Mayne Pharma Articles
Mayne Pharma to acquire Kapanol in Australia from GlaxoSmithKline for up to A$14.0 million
16 December 2012
Mayne Pharma acquires Metrics for upfront $105 million
9 October 2012
Pharmaceutical M&A deals in 2009
4 February 2010
Hospira to buy Orchid's generic injectable business for $400 million
16 December 2009
HalcyGen to buy fellow Australian drugmaker Mayne Pharma for $15 million
25 September 2009
Warner Chilcott gets FDA response to citizens petition
23 March 2009
FDA asks for Ph III trial for Subazole approval
10 December 2007
CEO: "supergenerics key to HalcyGen's future"
9 July 2007
HalcyGen to target $1B drugs sector
11 June 2007
Hospira's Mayne buy cleared by US FTC
29 January 2007
Hospira buys Mayne Pharma for $2.0 B
2 October 2006
Rumors that Mayne will float on the LSE
11 September 2006
Pliva and Mayne amend G-CSF deal
7 August 2006
LTKfarma established in France
17 July 2006
Supergen sells US Nipent rights to Mayne
3 July 2006
Mayne may sell Puerto Rico plant
27 March 2006
Pharma/biotech mergers and acquisitions during 2005
6 February 2006
Mayne gets US appro for multi-dose carboplatin
1 August 2005
Mayne to go ahead with demerger plan
27 June 2005
Mylan settles paclitaxel litigation
12 July 2004
aaiPharma sells MVI and Aquasol business to Mayne
15 March 2004
AEterna signs deal to sell Neovastat in Korea
31 March 2003
Lorus granted patent in Mexico for its Virulizin
24 February 2003
Showing 1-28 of 28 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
